These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30198569)

  • 21. The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.
    Bodur C; Kazyken D; Huang K; Ekim Ustunel B; Siroky KA; Tooley AS; Gonzalez IE; Foley DH; Acosta-Jaquez HA; Barnes TM; Steinl GK; Cho KW; Lumeng CN; Riddle SM; Myers MG; Fingar DC
    EMBO J; 2018 Jan; 37(1):19-38. PubMed ID: 29150432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational analysis of an autophagy/translation switch based on mutual inhibition of MTORC1 and ULK1.
    Szymańska P; Martin KR; MacKeigan JP; Hlavacek WS; Lipniacki T
    PLoS One; 2015; 10(3):e0116550. PubMed ID: 25761126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.
    Kelsey I; Zbinden M; Byles V; Torrence M; Manning BD
    Sci Rep; 2017 Nov; 7(1):16112. PubMed ID: 29170467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
    Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
    Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168.
    Xie X; Hu H; Tong X; Li L; Liu X; Chen M; Yuan H; Xie X; Li Q; Zhang Y; Ouyang H; Wei M; Huang J; Liu P; Gan W; Liu Y; Xie A; Kuai X; Chirn GW; Zhou H; Zeng R; Hu R; Qin J; Meng FL; Wei W; Ji H; Gao D
    Nat Cell Biol; 2018 Mar; 20(3):320-331. PubMed ID: 29403037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling.
    Yan Y; Ollila S; Wong IPL; Vallenius T; Palvimo JJ; Vaahtomeri K; Mäkelä TP
    Nat Commun; 2015 Nov; 6():8979. PubMed ID: 26616021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
    Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
    Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AMPK and autophagy get connected.
    Hardie DG
    EMBO J; 2011 Feb; 30(4):634-5. PubMed ID: 21326174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.
    Hutter G; Zimmermann Y; Rieken M; Hartmann E; Rosenwald A; Hiddemann W; Dreyling M
    Leukemia; 2012 Nov; 26(11):2442-4. PubMed ID: 22552006
    [No Abstract]   [Full Text] [Related]  

  • 31. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.
    Kan JY; Yen MC; Wang JY; Wu DC; Chiu YJ; Ho YW; Kuo PL
    Oncotarget; 2016 May; 7(21):31336-49. PubMed ID: 27150059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lysosome: a crucial hub for AMPK and mTORC1 signalling.
    Carroll B; Dunlop EA
    Biochem J; 2017 Apr; 474(9):1453-1466. PubMed ID: 28408430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide CRISPR screens reveal multitiered mechanisms through which mTORC1 senses mitochondrial dysfunction.
    Condon KJ; Orozco JM; Adelmann CH; Spinelli JB; van der Helm PW; Roberts JM; Kunchok T; Sabatini DM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33483422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
    Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.
    Darido C; Georgy SR; Cullinane C; Partridge DD; Walker R; Srivastava S; Roslan S; Carpinelli MR; Dworkin S; Pearson RB; Jane SM
    Cell Death Differ; 2018 Jun; 25(6):1146-1159. PubMed ID: 29238073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
    van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
    Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonistic control of muscle cell size by AMPK and mTORC1.
    Mounier R; Lantier L; Leclerc J; Sotiropoulos A; Foretz M; Viollet B
    Cell Cycle; 2011 Aug; 10(16):2640-6. PubMed ID: 21799304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.